Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
76 studies found for:    pci-32765
Show Display Options
Rank Status Study
1 Completed A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants
Condition: Healthy Volunteer
Interventions: Drug: PCI-32765 (Treatment A);   Drug: PCI-32765 (Treatment B);   Drug: PCI-32765 (Treatment C);   Drug: 13C6 PCI-32765 (reference)
2 Completed A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765
Condition: Healthy Volunteers
Interventions: Drug: Sequence 1: PCI-32765;   Drug: Sequence 2: PCI-32765;   Drug: Sequence 3: PCI-32765;   Drug: Sequence 4: PCI-32765;   Drug: Sequence 5: PCI-32765
3 Completed A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants
Condition: Healthy Participants
Intervention: Drug: Ibrutinib
4 Active, not recruiting Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
Condition: Leukemia
Interventions: Other: Heavy Water (2H2O);   Drug: PCI-32765
5 Completed A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants
Condition: Healthy Participants
Interventions: Drug: PCI-32765;   Drug: Rifampin
6 Not yet recruiting A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Behavioral: Phone Calls
7 Active, not recruiting PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Conditions: Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Other: Correlative laboratory samples;   Other: quality of life assessment
8 Completed A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
Condition: Hepatic Impairment
Intervention: Drug: PCI-32765
9 Recruiting Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Lymphoma, Mantle-cell
Intervention: Drug: Ibrutinib
10 Completed A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food
Condition: Healthy Volunteer
Interventions: Drug: Treatment A: PCI-32765;   Drug: Treatment B: PCI-32765
11 Recruiting Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Condition: Recurrent Adult Diffuse Large Cell Lymphoma
Interventions: Drug: Ibrutinib;   Biological: Rituximab;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
12 Recruiting Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Conditions: Adult B Acute Lymphoblastic Leukemia;   Chronic Lymphocytic Leukemia;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   HIV Infection;   Intraocular Lymphoma;   Multicentric Angiofollicular Lymphoid Hyperplasia;   Nodal Marginal Zone Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Plasma Cell Myeloma;   Small Intestinal Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Ibrutinib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
13 Recruiting A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants
Condition: Healthy
Interventions: Drug: Ibrutinib;   Drug: Moxifloxacin;   Drug: Ibrutinib-matching placebo;   Drug: Moxifloxacin-matching placebo
14 Recruiting Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)
Condition: Leukemia
Interventions: Drug: Ibrutinib;   Drug: Rituximab
15 Completed A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants
Condition: Healthy
Interventions: Drug: Ibrutinib;   Drug: Ketoconazole
16 Active, not recruiting A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
Condition: Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
17 Active, not recruiting A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms
Condition: Recurrent Mature B-cell Neoplasms
Intervention: Drug: PCI-32765
18 Recruiting A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone (or equivalent)
19 Not yet recruiting Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
Condition: Lymphoma
Intervention: Drug: Ibrutinib
20 Enrolling by invitation A Long-term Extension Study of PCI-32765 (Ibrutinib)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B-cell Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years